KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin (2019 - 2026)

Esperion Therapeutics filings provide 7 years of FCF Margin readings, the most recent being 26.86% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 7743.0% to 26.86% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.25%, a 397.0% increase, with the full-year FY2025 number at 3.25%, up 397.0% from a year prior.
  • FCF Margin hit 26.86% in Q4 2025 for Esperion Therapeutics, up from 4.91% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 39.03% in Q1 2024 to a low of 1116.42% in Q1 2021.
  • Median FCF Margin over the past 5 years was 105.44% (2023), compared with a mean of 182.39%.
  • The widest YoY moves for FCF Margin: up 267461bps in 2021, down -18323bps in 2021.
  • Esperion Therapeutics' FCF Margin stood at 374.69% in 2021, then soared by 40bps to 225.7% in 2022, then soared by 49bps to 114.9% in 2023, then soared by 56bps to 50.57% in 2024, then surged by 153bps to 26.86% in 2025.
  • The last three reported values for FCF Margin were 26.86% (Q4 2025), 4.91% (Q3 2025), and 38.14% (Q2 2025) per Business Quant data.